

## VANC Pharmaceuticals Announces Change of Auditor

May 17, 2016 – VANC Pharmaceuticals Inc. (“VANC” or the “Company”), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the “OTC”) markets, is pleased to announce that the board of directors of the Company has appointed Adam Sung Kim Ltd., Chartered Professional Accountants as the Company’s new auditor, replacing Smythe LLP, Chartered Accountants. The Company has filed a Notice of Change of Auditors in respect of this change under its profile on SEDAR at [www.sedar.com](http://www.sedar.com).

On behalf of:

VANC Pharmaceuticals Inc.

Arun Nayyar CEO

[anayyar@vancpharm.com](mailto:anayyar@vancpharm.com)

For further information, please contact CORE Capital Partners Inc., Ph: 604-566-9233.

Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves VANC’s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. VANC generally uses words such as “outlook,” “will,” “could,” “would,” “might,” “remains,” “to be,” “plans,” “believes,” “may,” “expects,” “intends,” “anticipates,” “estimate,” “future,” “plan,” “positioned,” “potential,” “project,” “remain,” “scheduled,” “set to,” “subject to,” “upcoming,” and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to VANC as of the date of this release, and VANC assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of VANC and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.